drugset
drugset / Trial / NCT04866160

A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated

NCT04866160 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following administration of multiple rising doses over 4 weeks and to explore the pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1291583 after multiple dosing and assess the PK/PD relationship.

Timeline

Start
2021-05-17
Primary completion
2021-11-30
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown — Oral

Indications

No indication recorded.